强肝胶囊联合干扰素α-2b治疗慢性乙型肝炎肝纤维化疗效分析  

Curative effect of Qianggan capsule combined with interferon α-2b in treatment of hepatic fibrosis of patient with chronic hepatitis B

作　　者：李长安[1] 杜敬佩[1] 王蕾[1] 王丹[1] 陈国荣[2] 

机构地区：[1]新乡医学院第三附属医院感染科,河南新乡453003 [2]新乡医学院第三附属医院肿瘤科,河南新乡453003

出　　处：《新乡医学院学报》2016年第9期757-760,共4页Journal of Xinxiang Medical University

基　　金：国家十二五科技重大专项课题(编号:2013ZX10002004;2013ZX10002005)

摘　　要：目的探讨强肝胶囊联合干扰素α-2b治疗慢性乙型肝炎肝纤维化的效果。方法 60例慢性乙型肝炎肝纤维化患者随机分为观察组和对照组,每组30例。观察组患者给予干扰素α-2b和强肝胶囊治疗48周。对照组患者仅给予干扰素α-2b治疗48周。所有患者在治疗前、治疗24、48周后进行肝弹性测定(LSM)、肝纤维化4项、肝功能、乙型肝炎病毒-DNA(HBV-DNA)定量测定,并观察临床症状及总有效率。结果治疗前2组患者的LSM、肝纤维化4项指标、肝功能3项指标比较差异均无统计学意义(P>0.05)。对照组患者治疗24周后的LSM与治疗前比较差异无统计学意义(P>0.05),治疗48周后的LSM与治疗前比较显著降低(P<0.05);治疗24周及48周后,对照组患者的肝纤维化4项指标与治疗前比较差异均无统计学意义(P>0.05),肝功能3项指标与治疗前比较差异均显著降低(P<0.05)。治疗24周及48周后,观察组患者的LSM值、肝纤维化4项指标、肝功能3项指标均显著低于治疗前(P<0.05);且观察组患者的LSM值、肝纤维化4项指标、肝功能3项指标均显著低于对照组(P<0.05)。治疗24周后,2组患者的HBV-DNA转阴率比较差异无统计学意义(P>0.05),观察组患者的HBV-DNA下降>1×106copies·L-1的比率和总有效率显著高于对照组(P<0.05)。治疗48周后,2组间HBV-DNA转阴率和HBV-DNA下降>1×106copies·L-1的比率比较差异无统计学意义(P>0.05),观察组患者的总有效率显著高于对照组(P<0.05)。治疗24、48周后,2组患者乏力、纳差、肝区不适、腹胀、尿黄、皮肤黄染者与治疗前比较均减少(P<0.05),且观察组患者乏力、纳差、尿黄、皮肤黄染者均少于对照组(P<0.05)。治疗48周后,观察组患者的显效率和总有效率均高于对照组(P<0.05)。结论强肝胶囊联合干扰素α-2b对慢性乙型肝炎肝纤维化有一定逆转作用,同时能有效改善肝脏功能,缓解临床症状,对乙型肝炎病毒的复制有一定的�Objective To explore the curative effect of the method of combining Qianggan capsule with interferon α-2b against hepatic fibrosis in patients with chronic hepatitis B. Methods Sixty patients with hepatic fibrosis with chronic hepatitis B were randomly divided into observation group and control group, with 30 cases in each group. The patients in the observation group were given interferon α-2b and Qianggan capsule for 48 weeks. The patients in the control group were given interferon α-2b only for 48 weeks. Liver stiffiness measurements （LSM） , four indexes of hepatic fibrosis, hepatic function, and hepatitis B virus （ HBV ） -DNA ration were observed before treatment, at 24 weeks and 48 weeks after treatment, and the recovery of clinical symptom and total therapeutic effect were observed too. Results There was no statistical significance in the LSM, four indexes of liver fibrosis and three indexes of liver function between the two groups of patients before treatment（ P 〉 0.05 ）. For the con- trol group, the LSM has no statistical significance between the pre-treatment and at 24 weeks after treatment （ P 〉 0.05 ） ; but it reduced significantly at 48 weeks after treatment （ P 〈 0.05 ） ; moreover, the four indexes of liver fibrosis had no statistical significance between the pre-treatment and at 24 weeks and 48 weeks after treatment （ P 〉 0.05 ）, while the liver functions reduced significantly（ P 〈 0.05 ）. For the observation group, the LSM, four indexes of liver fibrosis and three indexes of liver function at 24 weeks and 48 weeks after treatment were lower than those of pre-treatment （ P 〈 0.05 ） and the control group （ P 〈 0.05 ）. After 24 weeks treatment, the contrast between both groups＇ negative rate of HBV-DNA had no statistical significance （P 〉 0. 05） ,while the rate of reducting more than 1 × 10^6 copies · L-1 of HBV-DNA in the observation group and total efficiency were higher than those of the control group（ P 〈 0.05 ）. After 48 weeks tr

关 键 词：强肝胶囊 干扰素Α-2B 慢性乙型肝炎肝纤维化 

分 类 号：R512[医药卫生—内科学]